Trastuzumab (Herceptin®) is an anti-cancer therapy that acts on the HER2/neu (erbB2) receptor. Herceptin's principal use is in breast cancer in patients whose tumors overexpress (produce more than the usual amount of) this receptor. Trastuzumab is administered either once a week or once every three weeks intravenously for 30 to 90 minutes.

Mechanism of action

---

Amplification of ErbB2 occurs in 30% of early-stage breast cancers (Bange et al 2001). It encodes the transmembrane tyrosine kinase p185-erbB2 glycoprotein. Although the signaling pathways induced by the erbB2 receptor are incompletely characterized, it is thought that activation of the PI3K/Akt pathway is important. This pathway is normally associated with mitogenic signaling involving the MAPK pathway. In cancer growth producing signals from erbB2 are constitutively transmitted, promoting invasion, survival and angiogenesis of cells (Ménard et al 2003). Furthermore overexpression can also confer therapeutic resistance to cancer therapies. Kute et al. (2004) suggest that the prime mechanism that causes increase in proliferation speed is due to induction of p27Kip1, an inhibitor of cdk2 and of cell proliferation, to remain in the cytoplasm instead of translocation in to the nucleus. This is caused by phosphorylation by Akt.

Herceptin is a monoclonal antibody which binds to the extracellular segment of the erbB2 receptor. Cells treated with Herceptin undergo arrest during the G1 phase of the cell cycle and experience a reduction in proliferation. It has been suggested that Herceptin induces some of its effect by downregulation of erbB2 leading to disruption of receptor dimerization and signaling through the downstream PI3K cascade. P27Kip1 is then not phosphorylated and is able to enter the nucleus and inhibit cdk2 activity, causing cell cycle arrest (Kute et al 2004). Also, Herceptin suppresses angiogenesis by induction of antiangiogenic factors and repression of proangiogenic factors. It is thought that a contribution to the unregulated growth observed in cancer could be due to proteolytic cleavage of erbB2 that results in the release of the extracellular domain. Herceptin has been shown to inhibit erbB2 ectodomain cleavage in breast cancer cells (Albenall et al 2003). There may be other undiscovered mechanisms by which Herceptin induces regression in cancer.

More on [ Trastuzumab ]

Trastuzumab - Twitter Search

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment: Roche/Ge... http://t.co/LL6J3IsW
Penny_Mearing (Penny Mearing) Fri, 03 Feb 2012 12:57:25 -0000
Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment: Roche/Ge... http://t.co/LL6J3IsW
Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment: Roche/Ge... http://t.co/WcIR3lks
Estela_Oshey (Estela Oshey) Fri, 03 Feb 2012 12:57:25 -0000
Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment: Roche/Ge... http://t.co/WcIR3lks
Subscribe to Trastuzumab RSS feed